Quantitative Detection of Residual E. coli Host Cell DNA by Real-Time PCR |
Lee, Dong-Hyuck
(Department of Biological Sciences, Hannam University)
Bae, Jung-Eun (Department of Biological Sciences, Hannam University) Lee, Jung-Hee (Department of Biological Sciences, Hannam University) Shin, Jeong-Sup (Quality Control Unit, Green Cross Corp.) Kim, In-Seop (Department of Biological Sciences, Hannam University) |
1 | Jeong, H. S., J. H. Shin, Y. N. Park, J. Y. Choi, Y. L. Kim, B. G.. Kim, et al. 2003. Development of real-time RT-PCR for evaluation of JEV clearance during purification of HPV type 16 L1 virus-like particles. Biologicals 31: 223-229. DOI ScienceOn |
2 | Swartz, J. R. 2001. Advances in Escherichia coli production of therapeutic proteins. Curr. Opin. Biotechnol. 12: 195-201. DOI ScienceOn |
3 | Nissom, P. M. 2007. Specific detection of residual CHO host cell DNA by real-time PCR. Biologicals 35: 211-215. DOI ScienceOn |
4 | Rathore, A. S., S. E. Sobacke, T. J. Kocot, D. R. Morgan, R. L. Dufield, and N. M. Mozier. 2003. Analysis for residual host cell proteins and DNA in process streams of a recombinant protein product expressed in Escherichia coli cells. J. Pharm. Biomed. Anal. 32: 1199-1211. DOI ScienceOn |
5 | Wang, K. U., Y. J. Guo, S. H. Sun, K. Shi, S. Zhang, K. H. Wang, Y. Zhang, and Z. H. Chen. 2006. 16S rRNA gene probe quantitates residual host cell DNA in pharmaceutical-grade plasmid DNA. Vaccine 24: 2656-2661. DOI ScienceOn |
6 | Rozen, S. and H. Skaletsky. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132: 365-386. |
7 | Vilalta, A., V. Whitlow, and T. Martin. 2002. Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Anal. Biochem. 301: 151-153. DOI ScienceOn |
8 | Walsh, G. 2002. Proteins Biochemistry and Biotechnology, pp. 205-206. John Wiley & Sons Ltd, West Sussex, England. |
9 | Wit, C., C. Fautz, and Y. Xu. 2000. Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture. Biologicals 28: 137-148. DOI ScienceOn |
10 | Wolf, J. J., L. Wang, and E. Wang. 2007. Application of PCR technology in vaccine product development. Expert Rev. Vaccines 6: 547-558. DOI ScienceOn |
11 | Wolter, T. and A. Richter. 2005. Assay for controlling host-cell impurities in biopharmaceuticals. BioProcess Int. 3: 40-46. |
12 | Workman, W. E. 1995. Sample preparation and residual DNA analysis of biopharmaceuticals. Pharmacopeia Forum 21: 479- 483. |
13 | Kung, V. T., P. R. Panfili, E. L. Sheldon, R. S. King, P. A. Nagainis, J. B. Gomez, D. A. Ross, J. Briggs, and R. F. Zuk. 1990. Picogram quantitation of total DNA using DNA-binding proteins in a silicon sensor-based system. Anal. Biochem. 187: 220-227. DOI ScienceOn |
14 | Martins, S. A. M., D. M. F. Prazeres, J. M. S. Cabral, and G. A. Monteiro. 2003. Comparison of real-time polymerase chain reaction and hybridization assays for the detection of Escherichia coli genomic DNA in process samples and pharmaceuticalgrade plasmid DNA products. Anal. Biochem. 322: 127-129. DOI ScienceOn |
15 | Lahijani, M., M. Duhon, E. Lusby, H. Betita, and M. Marquet. 1988. Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive PCR and enzyme linked immunosorbent assay. Hum. Gene Ther. 9: 1173-1180. |
16 | Lee, D. H., H. S. Jeong, T. E. Kim, S. H. Oh, J. Lee, and I. S. Kim. 2008. Real-time RT-PCR for validation of reovirus type 3 safety during the manufacture of mammalian cell culturederived biopharmaceuticals. Kor. J. Microbiol. 44: 228-236. 과학기술학회마을 |
17 | Lovatt, A. 2002. Applications of quantitative PCR in the biosafety and genetic stability assessment of biotechnology products. Rev. Mol. Biotechnol. 82: 279-300. DOI ScienceOn |
18 | Monis, P. T. and S. Giglio. 2006. Nucleic acid amplificationbased techniques for pathogen detection and identification. Infect. Genet. Evol. 6: 2-12. DOI ScienceOn |
19 | CPMP. 1997. Position Statement on DNA and host cell proteins (HCP) impurities - routine testing versus validation studies. Biotechnology Working Party, Committee for Proprietary Medicinal Product, The European Agency for the Evaluation of Medicinal Product, Human Medicines Evaluation Unit, EU. |
20 | CPMP. 2001. Position statement on the use of tumourigenic cells of human origin for the production of biological and biotechnological medicinal products. Biotechnology Working Party, Committee for Proprietary Medicinal Product, The European Agency for the Evaluation of Medicinal Products: Evaluation of Medicinal Products for Human Use, EU. |
21 | FDA. 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, U.S.A. |
22 | FDA. 2001. Guidance for industry, bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Veterinary Medicine, U.S.A. |
23 | ICH. 1996. Q2B Validation of analytical procedures: Methodology (guidance for industry). International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. |
24 | Jana, S. and J. K. Deb. 2005. Strategies for efficient production of heterologous proteins in Escherichia coli. Appl. Microbiol. Biotechnol. 67: 289-298. DOI ScienceOn |
25 | Kubista, M., J. M. Andrade, M. Bengtsson, A. Forootan, J. Jonák, K. Lind, et al. 2006. The real-time polymerase chain reaction. Mol. Aspects Med. 27: 95-125. DOI ScienceOn |
26 | Brosius, J., T. J. Dull, D. D. Sleeter, and H. F. Noller. 1981. Gene organization and primary structure of a ribosomal RNA operon from Escherichia coli. J. Bacteriol. 62: 293-300. |
27 | Banexy, F. 1999. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 10: 411-421. DOI ScienceOn |